| 1 |
33432065 | Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. | 2021 Jan 11 |
4 |
| 2 |
30786012 | Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study. | 2019 Sep |
1 |
| 3 |
29479969 | Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy | 2018 Feb 26 |
1 |
| 4 |
30022682 | Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay. | 2018 Aug 1 |
3 |
| 5 |
28798474 | CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset. | 2017 Aug 10 |
1 |
| 6 |
26799162 | Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. | 2016 Jun |
3 |
| 7 |
27198207 | Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. | 2016 Dec |
2 |
| 8 |
25940823 | Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. | 2015 Aug |
1 |
| 9 |
25339025 | Association of CYP2C19 polymorphisms with survival of breast cancer patients using tamoxifen: results of a meta- analysis. | 2014 |
4 |
| 10 |
23604525 | Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies. | 2013 Jun |
1 |
| 11 |
23736997 | CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. | 2013 Jun |
8 |
| 12 |
23776391 | Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. | 2013 |
4 |
| 13 |
23781139 | Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer. | 2013 |
2 |
| 14 |
20309015 | Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. | 2011 Apr |
1 |
| 15 |
21185724 | Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. | 2011 Apr |
2 |
| 16 |
21480951 | Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. | 2011 May |
2 |
| 17 |
21830868 | The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. | 2011 Aug |
3 |
| 18 |
21906462 | The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. | 2011 Sep |
1 |
| 19 |
21961651 | SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. | 2011 Nov |
1 |
| 20 |
20565970 | Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. | 2010 Jun 21 |
3 |
| 21 |
21047200 | CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. | 2010 Oct |
7 |
| 22 |
18024866 | Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. | 2007 Nov 20 |
1 |
| 23 |
16550168 | Cytochrome P450 pharmacogenetics and cancer. | 2006 Mar 13 |
1 |
| 24 |
12419838 | Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. | 2002 Nov |
1 |